Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism

Area of Science:

• Oncology
• Molecular Biology
• Metabolomics

Background:

• Anlotinib, a receptor tyrosine kinase (RTK) inhibitor, shows anti-angiogenic effects.
• Tumor metabolic reprogramming mechanisms influenced by anlotinib remain largely unknown.

Purpose of the Study:

• Investigate anlotinib's effects on tumor metabolite distribution and expression.
• Identify key metabolic pathways modulated by anlotinib treatment.

Main Methods:

• Spatial metabolomics analysis of tumor tissues.
• Integration of transcriptomics and proteomics data.
• Analysis of metabolic pathway modulation.

Main Results:

• Anlotinib significantly altered metabolite levels in tumors.
• Four primary metabolic pathways were modulated: taurine and hypotaurine metabolism, steroid synthesis, pentose phosphate pathway, and lipid biosynthesis.
• Key compounds like sulfonic acids, cholesterol, inositol phosphate pyrophosphate, and palmitoyl-CoA were affected.

Conclusions:

• Anlotinib influences tumor initiation and progression through metabolic reprogramming.
• Identified metabolic pathways and compounds serve as potential biomarkers for anlotinib therapy.
• This study provides insights into anlotinib's anti-cancer mechanisms at a metabolic level.